A Proof of Concept Study for Preemptive Treatment With Grazoprevir and Elbasvir in Donor HCV-positive to Recipient HCV-negative Cardiac Transplant

Trial Profile

A Proof of Concept Study for Preemptive Treatment With Grazoprevir and Elbasvir in Donor HCV-positive to Recipient HCV-negative Cardiac Transplant

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Elbasvir/grazoprevir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 11 Jul 2017 Planned initiation date changed from 1 Jul 2017 to 1 Dec 2017.
    • 27 Apr 2017 Planned initiation date changed from 1 Apr 2017 to 1 Jul 2017.
    • 01 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top